ArticleDiabetology & metabolic syndrome2025
Sequential use of continuous glucose monitoring, with or without exercise trackers, significantly improves glycemic control in patients with type 2 diabetes.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Technology-Enhanced Exercise Training for Cardiometabolic Syndrome: A Scoping Review.Journal of functional morphology and kinesiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsContinuous glucose monitoring systems (CGM) and exercise trackers offer real-time feedback on the effects of lifestyle intervention on blood glucose. This randomized controlled trial aimed to examine whether an additional exercise tracker (Fitbit) would improve glycemic control, in combination with sequential CGM (FreeStyle Libre), in middle-aged patients with Type 2 Diabetes.
methodsThis 6-month prospective study included 158 patients, of whom 138 participants completed the protocol, with a median age of 58 (54, 62) years and HbA1c of 9.7% (8.8, 10.4). There were 69.6% participants on insulin therapy. Participants were randomly assigned to one of two groups: a group wearing a CGM alone (CGM, n = 73) or a group wearing both a CGM and a Fitbit INSPIRE HR (CGM-Fit, n = 65). All participants wore three sequential CGM (2 weekly for 6 weeks), coupled with diabetes education and diet counselling.
resultsBoth groups demonstrated sufficient CGM data capture at each two weeks (89.8%, 90.8%, 92%), with an average wear time of 14 days and 6-7 scans per day. Overall, time-in-range increased (61%, 67%, 71%; p < 0.01) and time-above-range decreased (35%, 27%, 25%; p < 0.01). HbA1c reduced significantly (p < 0.0001) between baseline and 3 months by 1.5% in both groups, independent of weight changes. However, between 3 and 6 months, the CGM group experienced a rise in HbA1c of 0.7% (p < 0.0001) compared (p < 0.05) to the 0.4% rise (p < 0.0001) in the CGM-fit group. The CGM-Fit group maintained their physical activity levels, whereas the CGM group experienced a significant reduction (p < 0.01) in physical activity.
conclusionsThe use of sequential CGM, guided by Diabetes counselling and dietary advice, significantly improved HbA1c. Using an exercise tracker may help sustain physical activity and glycemic control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.